Navigation Links
Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference

PLYMOUTH MEETING, Pa., Dec. 4 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that Jack Armstrong, President and CEO of Genaera, is scheduled to present at the 2008 RBC Capital Markets Healthcare Conference. The presentation is part of an RBC Capital Markets' panel discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will take place at the Westin Times Square Hotel in New York on Wednesday, December 11 at 11:00 a.m. ET.

This panel presentation is being webcast at:

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera to Present at Therapeutic Area Partnerships 2008
2. Genaera Receives Non-Compliance Notice From NASDAQ
3. Genaera Corporations 2008 Annual Stockholder Meeting Results
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
6. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
7. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
8. ATS Medical to Participate at the RBC Capital Markets Healthcare Conference
9. Individuals Associated with Vinson Hall Retirement Community, Who Survived Pearl Harbor Attack, to Participate in Navy Memorial Event December 7
10. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... The McHenry County ... recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. ... Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... in both surgical and non-surgical treatments, announced the expansion of his private practice ... Surgery. , Highly trained and nationally recognized for his natural approach, Dr. ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... provide scholarships for people struggling with eating disorders as a result of the ... second annual event, held at Fox Run Golf Club in Eureka, will help ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract ... significant expansion of its current state of the art research, development and manufacturing ... to increase its manufacturing capacity as well as to support its clients’ growing ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Endo International plc (NASDAQ: ENDP ) ... President and CEO, will discuss corporate updates at the 27 ... New York on Wednesday, December 2, 2015 at ... Investor Relations, and then the link to the event. Participants ... time to visit the site and download any streaming media ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
Breaking Medicine Technology: